The use of tenoxicam in active axial spondyloarthritis – focus on efficacy and safety

Purpose of the study – to study the efficacy and safety of tenoxicam (Texared®) in patients with active axial spondyloarthritis.
Material and methods. The study included 35 patients with active axial spondyloarthritis with BASDAI≥4.0. Patients were given continuous oral tenoxicam (Texared®, Dr. Reddy’s Laboratories) at a dosage of 20 mg/day. Subsequently, 5 patients were excluded from the study due to discontinuation of the drug after 5–10 days of administration. 30 patients were included in the final analysis. Initially and after 30 days, to assess the severity of pain and stiffness, activity, patients filled out questionnaires in electronic form using Google forms, a general assessment of pain in the lower back and the intensity of night pain by the patient, subjective sleep characteristics were carried out. The doctor calculated the BASDAI, ASDAS-CRP, BASMI indices, and evaluated the activity according to the doctor’s opinion. The baseline blood pressure level was determined, and a patient diary was issued for ambulatory blood pressure measurement in the morning/evening for 30 days. After 30 days, the patient’s ambulatory blood pressure control was assessed. At baseline and after 30 days, biochemical blood parameters were studied, including a complete blood and urine test.
Results and conclusion. In patients with axial spondyloarthritis with high and very high activity, a positive effect of tenoxicam (Texared®) therapy on disease activity was noted. The effect of Texared® develops with regular use already during the first 2 weeks, and after 4 weeks there is a clear decrease in the severity of pain in the lower back, a decrease in the duration of morning stiffness. The drug is well tolerated, has a favorable safety profile, no serious adverse events and few side effects that do not require discontinuation of therapy.

1. Gaidukova IZ, Mazurov VI. The efficacy of non-steroidal anti-inflammatory drugs. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(5): 134-140 (In Russ.)]. doi: 10.17116/jnevro2019119051134

2. Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One. 2013;8(5):e63451. doi: 10.1371/journal.pone.0063451

3. Kumagai K, Kubo M, Imai S, Toyoda F, Maeda T, Okumura N, et al. The COX-2 selective blocker etodolac inhibits TNFα-induced apoptosis in isolated rabbit articular chondrocytes. Int J Mol Sci. 2013;14(10):19705-19715. doi: 10.3390/ijms141019705

4. Dong X, Li R, Xiu P, Dong X, Xu Z, Zhai B, et al. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX2-dependent and -independent pathways. PLoS One. 2014;9(3):e92864. doi: 10.1371/journal.pone.0092864

5. Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: A Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75(6):1152-1160. doi: 10.1136/annrheumdis-2015-207677

6. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(8):1369-1374. doi: 10.1136/ard.2010.145995

7. Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum. 2005;52(6):1756-1765. doi: 10.1002/art.21054

8. Karateev AE. Non-steroidal anti-inflammatory drugs use in clinical practice: New opportunities. Consilium Medicum. 2018;20(9):88-94 (In Russ.)]. doi: 10.26442/2075-1753_2018.9.88-94